Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05153148 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

A Phase 2 study, sponsored by Takeda.

Completed
Registry status
Phase 2
Development phase
305
Enrollment target

NCT05153148: Completed Phase 2 study, sponsored by Takeda.

NCT05153148 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 305 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (129% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05153148, a Phase 2 study, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 2
Development phase
305 participants
Enrollment target

Study Summary

This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).

Primary Outcome

ACR20 is composite measure defined as improvement of 20 percent(%) from baseline in both number of tender (68) \& number of swollen (66) joints \& a 20% improvement in at least 3 of following 5 criteria: patient global assessment of psoriatic arthritis (PGA-PsA) \[visual analog scale (VAS) where, 0=very good, no symptoms \& 100=very poor, severe symptoms\], physician global assessment of psoriatic arthritis (PhGA-PsA) \[(VAS) where 0=no disease activity \& 100=maximum disease activity\], patient

Interventions

  • OTHER Placebo
  • DRUG NDI-034858

Trial Details

FieldValue
Enrollment Target 305 participants
Start Date 2022-01-06
Est. Completion 2023-06-02
Phase Phase 2
Takeda

408 total trials

What the finished NCT05153148 record still lists

NCT05153148 is an interventional study that assigns participants to a tested intervention. The registered 305 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (129% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05153148 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05153148 about?

NCT05153148 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis". This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).

What is the current status of trial NCT05153148?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 305 participants. The study started on 2022-01-06. Estimated completion is 2023-06-02.

What interventions are being tested in trial NCT05153148?

The interventions under investigation include: Placebo (OTHER), NDI-034858 (DRUG).

Who is sponsoring clinical trial NCT05153148?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05153148's enrollment target sits among peer trials

305 166th of 2000 higher than 1,835 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04107181 · 305 participants · NA

    Pilot Study for Speculum Free Cervical Cancer Screening

  • NCT05399056 · 305 participants · NA

    Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling

  • NCT05078970 · 306 participants · NA

    Advancing Suicide Intervention Strategies for Teens During High Risk Periods

  • NCT05843695 · 306 participants · NA

    Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05153148, the US trial registry maintained by the National Library of Medicine. NCT05153148 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.